Ocugen Inc Dossier
Qualitative Analysis
Business overview
Ocugen, Inc. (NASDAQ: OCGN) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative gene and cell therapies, biologics, and vaccines. The company's primary value driver is its breakthrough modifier gene therapy platform, which utilizes nuclear hormone receptors (NHRs) to restore cellular homeostasis and address complex retinal diseases in a gene-agnostic manner. Its lead clinical candidate, OCU400, is currently in Phase 3 clinical trials (the liMeliGhT study) for retinitis pigmentosa. Other key pipeline assets include OCU410 for geographic atrophy secondary to dry age-related macular degeneration (dAMD) and OCU410ST for Stargardt disease. Additionally, Ocugen is developing OCU200 for diabetic macular edema and wet AMD, alongside mucosal vaccine candidates targeting COVID-19 and seasonal influenza.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing a synchronized, gene-agnostic modifier gene therapy pipeline (OCU400, OCU410, OCU410ST) targeting rare and underserved retinal diseases to support three BLA filings within three years.
Expected impact: Establishes Ocugen as a commercial-stage leader in ophthalmology gene therapies, addressing large global patient populations with high unmet needs.
Creating OrthoCellix as a wholly-owned subsidiary to house regenerative cell therapy assets, including NeoCart, with the goal of securing independent financing.
Expected impact: Allows Ocugen to focus its core capital on its modifier gene therapy platform while maximizing the value of its orthopedic regenerative assets.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Grants Kwangdong exclusive rights to develop and commercialize OCU400 in South Korea, utilizing Ocugen's clinical data for local regulatory approval.
Terms: Upfront license fees and near-term development milestones of up to $7.5 million, sales milestones of $1.5 million for every $15 million of sales (projected up to $180 million over 10 years), and a 25% royalty on net sales. Ocugen retains commercial manufacturing rights.
Collaborative development and manufacturing partnership for Ocugen's modifier gene therapy platform, including OCU400, OCU410, and OCU410ST.
Terms: Collaborative arrangement revenue recognized over time (including $4.61 million for the nine months ended September 30, 2025).